GlassScriptPhysician profile
Sepideh Panahi
NPI 1083032304
$2,187.43
in general payments reported to CMS, 2019-2025
24 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $350 · 2021: $420 · 2022: $405 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $436.04 | 2019-2021 | |
| Genzyme Corporation | $350.00 | 2020 | |
| Mdd US Operations, LLC | $167.43 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $164.18 | 2019-2022 | |
| Abbvie INC. | $148.39 | 2021-2022 | |
| Medtronic Vascular, INC. | $120.93 | 2019 | |
| Eisai INC. | $100.80 | 2025 | |
| Sunovion Pharmaceuticals INC. | $98.93 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $79.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $59.78 | 2019 | |
| Neurocrine Biosciences, INC. | $56.33 | 2019 | |
| Argenx US, INC. | $54.89 | 2025 | Vyvgart Hytrulo |
| Amgen INC. | $46.15 | 2019 | |
| Greenwich Biosciences, INC. | $44.89 | 2019 | |
| Upsher-Smith Laboratories LLC | $44.31 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $43.49 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.00 | 2019 | |
| Kyowa Kirin, INC. | $28.49 | 2021 | |
| Lilly USA, LLC | $25.58 | 2019 | |
| Avion Pharmaceuticals | $24.25 | 2022 | |
| Biogen, INC. | $15.00 | 2019 | |
| Currax Pharmaceuticals LLC | $14.95 | 2022 | |
| Ucb, INC. | $14.68 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sepideh Panahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.